Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Joachim Stemmler

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
The Oncologist|July 11, 2008
Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challengeHans-Joachim Stemmler, Volker Heinemann
Deutsche Medizinische Wochenschrift (1946)|May 29, 2026
[Critical care management as part of oncological therapy]Hans Joachim Stemmler, Alessia Fraccaroli, Michael von Bergwelt-Baildon
Anti-Cancer Drugs|September 23, 2009
UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?Christoph Schulz, Stefan Boeck, Volker Heinemann, et al.
Anti-Cancer Drugs|August 4, 2010
Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?Sandra Geiger, Marcus Schlemmer, Volker Heinemann, et al.
Onkologie|February 5, 2005
Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumabHans-Joachim Stemmler, Petra Stieber, Dorit Lässig, et al.
Anti-Cancer Drugs|April 9, 2010
Anticancer therapy induced cardiotoxicity: review of the literatureSandra Geiger, Veronika Lange, Patricia Suhl, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 29, 2010
Prognostic parameters and risk stratification in intensive care patients with severe liver diseasesSebastian Lehner, Hans Joachim Stemmler, Alexander Mück, et al.
Onkologie|October 27, 2005
Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC)Hans-Joachim Stemmler, Steffen Kahlert, Wolfgang Siekiera, et al.
Anti-Cancer Drugs|December 13, 2006
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrierHans-Joachim Stemmler, Manfred Schmitt, Amina Willems, et al.
Acta Cardiologica|May 31, 2012
Mechanical ventilation with positive end-expiratory pressure in critically ill patients: comparison of CW-Doppler ultrasound cardiac output monitoring (USCOM) and thermodilution (PiCCO)Sophia Horster, Hans Joachim Stemmler, Jakob Sparrer, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
The Oncologist|July 11, 2008
Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challengeHans-Joachim Stemmler, Volker Heinemann
Deutsche Medizinische Wochenschrift (1946)|May 29, 2026
[Critical care management as part of oncological therapy]Hans Joachim Stemmler, Alessia Fraccaroli, Michael von Bergwelt-Baildon
Anti-Cancer Drugs|September 23, 2009
UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?Christoph Schulz, Stefan Boeck, Volker Heinemann, et al.
Anti-Cancer Drugs|August 4, 2010
Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?Sandra Geiger, Marcus Schlemmer, Volker Heinemann, et al.
Onkologie|February 5, 2005
Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumabHans-Joachim Stemmler, Petra Stieber, Dorit Lässig, et al.
Anti-Cancer Drugs|April 9, 2010
Anticancer therapy induced cardiotoxicity: review of the literatureSandra Geiger, Veronika Lange, Patricia Suhl, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 29, 2010
Prognostic parameters and risk stratification in intensive care patients with severe liver diseasesSebastian Lehner, Hans Joachim Stemmler, Alexander Mück, et al.
Onkologie|October 27, 2005
Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC)Hans-Joachim Stemmler, Steffen Kahlert, Wolfgang Siekiera, et al.
Anti-Cancer Drugs|December 13, 2006
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrierHans-Joachim Stemmler, Manfred Schmitt, Amina Willems, et al.
Acta Cardiologica|May 31, 2012
Mechanical ventilation with positive end-expiratory pressure in critically ill patients: comparison of CW-Doppler ultrasound cardiac output monitoring (USCOM) and thermodilution (PiCCO)Sophia Horster, Hans Joachim Stemmler, Jakob Sparrer, et al.
Pageof 5